Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dyne Therapeutics ( (DYN) ) has provided an update.
On December 8, 2025, Dyne Therapeutics, Inc. amended its Loan and Security Agreement with Hercules Capital, Inc. and other lenders, allowing the company to borrow a second term loan tranche of $50 million. This amendment provides Dyne Therapeutics with additional financial flexibility, enabling access to further tranches totaling up to $125 million, contingent on achieving certain milestones, and extends the interest-only payment period under specific conditions.
The most recent analyst rating on (DYN) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.
Spark’s Take on DYN Stock
According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.
Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.
To see Spark’s full report on DYN stock, click here.
More about Dyne Therapeutics
Average Trading Volume: 2,630,930
Technical Sentiment Signal: Buy
Current Market Cap: $2.9B
For an in-depth examination of DYN stock, go to TipRanks’ Overview page.